KRSNAA NSE filing

Krsnaa Diagnostics Q1 FY26: Rajasthan Award & Retail Growth Drive Performance

The RealCase readHigh impact Positive

Why it matters

The Rajasthan award is a large, transformative project and the retail growth signifies a major expansion, both expected to significantly impact revenue and operations.

The market read

The announcement highlights strong financial results, significant growth in retail, and a transformative new order in Rajasthan, indicating positive prospects for the company.

* Krsnaa Diagnostics reported Q1 FY26 revenue of ₹19.30 crore, a 13% year-on-year growth. * EBITDA stood at ₹5.24 crore with a 27% margin, and PAT at ₹2.05 crore with an 11% margin. * The company served 5 million patients and processed 16 million tests. * Retail touchpoints surged to 2,414, with retail contributing 6% of overall group revenues. * The company announced the Rajasthan award, a transformative achievement with 42 mother labs, 135 satellite labs, and 1,300-plus collection centers, targeted for full operations by FY26 with material revenues starting from FY27. * The company is scaling rapidly in Maharashtra, Punjab, Assam, and Odisha, leveraging PPP hubs for logistics and QA. * Upon completion of the current order book, Krsnaa will be operating 200-plus CT scan MRI centers. * Management Commentary: Diagnostics in India is in the midst of a multi-year up cycle. Radiology is set to grow even faster as advanced modalities penetrate beyond metros, translating into rising volumes, greater formalization and a clear opening for scaled tech-enabled platforms to win share. Krsnaa is uniquely positioned to lead this growth.

Filing to action

What to do with a filing like this

Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.

View original filing